JP2024524895A - 抗ｃｓｐ抗体 - Google Patents

抗ｃｓｐ抗体 Download PDF

Info

Publication number
JP2024524895A
JP2024524895A JP2023576368A JP2023576368A JP2024524895A JP 2024524895 A JP2024524895 A JP 2024524895A JP 2023576368 A JP2023576368 A JP 2023576368A JP 2023576368 A JP2023576368 A JP 2023576368A JP 2024524895 A JP2024524895 A JP 2024524895A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524895A5 (enExample
Inventor
エマーリング、ダニエル、エリック
ケッチェム、ランダル、アール
リッパウ、ショーン、エム
ヴォルクムース、ウェイン
ウィリアムズ、キャサリン、エル
Original Assignee
アトレカ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトレカ インコーポレイテッド filed Critical アトレカ インコーポレイテッド
Publication of JP2024524895A publication Critical patent/JP2024524895A/ja
Publication of JP2024524895A5 publication Critical patent/JP2024524895A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023576368A 2021-06-17 2022-06-16 抗ｃｓｐ抗体 Pending JP2024524895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
US63/211,820 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Publications (2)

Publication Number Publication Date
JP2024524895A true JP2024524895A (ja) 2024-07-09
JP2024524895A5 JP2024524895A5 (enExample) 2025-06-23

Family

ID=84526612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576368A Pending JP2024524895A (ja) 2021-06-17 2022-06-16 抗ｃｓｐ抗体

Country Status (9)

Country Link
US (2) US11655290B2 (enExample)
EP (1) EP4355774A4 (enExample)
JP (1) JP2024524895A (enExample)
KR (1) KR20240047964A (enExample)
CN (1) CN117940450A (enExample)
AU (2) AU2022292722B2 (enExample)
IL (1) IL309422A (enExample)
MX (1) MX2023014984A (enExample)
WO (1) WO2022266383A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024214379A1 (en) * 2023-02-03 2025-08-21 Atreca, Inc. Anti-csp antibody variants
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN103732738A (zh) * 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
TW201708260A (zh) 2015-07-22 2017-03-01 優瑞卡醫療公司 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途
US11066464B2 (en) * 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US20220195023A1 (en) 2019-02-19 2022-06-23 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
EP4355774A4 (en) 2025-05-07
US20230167169A1 (en) 2023-06-01
NZ806561A (en) 2025-06-27
US11655290B2 (en) 2023-05-23
CN117940450A (zh) 2024-04-26
KR20240047964A (ko) 2024-04-12
IL309422A (en) 2024-02-01
US20230002483A1 (en) 2023-01-05
WO2022266383A1 (en) 2022-12-22
MX2023014984A (es) 2024-03-12
AU2025220692A1 (en) 2025-09-11
AU2022292722A1 (en) 2024-01-04
US12545723B2 (en) 2026-02-10
EP4355774A1 (en) 2024-04-24
AU2022292722B2 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
TWI778994B (zh) 用於移除造血幹細胞的抗體藥物結合物
TW201819413A (zh) Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
JP7308747B2 (ja) 抗インターフェロンガンマ抗体およびその使用法
JP7538131B2 (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
TW200836763A (en) Pegylated Aβ FAB
WO2022184074A1 (zh) 含抗tslp抗体的药物组合物
US20190389939A1 (en) Antibody against hepatitis b surface antigen and use thereof
US12545723B2 (en) Anti-CSP antibodies
JP2026016483A (ja) 抗ヒトｔｌｒ７抗体
JPWO2018070390A1 (ja) 抗ｒｏｂｏ４抗体と他剤を含む組成物
JP2022507599A (ja) 安定性が向上した抗ｃ－ｍｅｔ抗体又はその抗原結合断片
CN115991784A (zh) 抗cd47-cldn18.2双特异性抗体及其用途
JP7748389B2 (ja) 抗ｃｄ４７抗体およびその使用
US20220195023A1 (en) Anti-csp antibody variants
OA21630A (en) Anti-CSP antibodies.
WO2025194069A1 (en) Anti-csp antibody variants
KR20260036054A (ko) 항-csp 항체 변이체
RU2817143C2 (ru) Антитело против cd79b, его антигенсвязывающий фрагмент и его фармацевтическое применение
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
WO2025217497A1 (en) Albumin binding proteins and methods of use
WO2025171256A1 (en) Compositions and methods for treating malaria
HK40059424B (zh) 抗cd79b抗体、其抗原结合片段及其医药用途
WO2021190500A1 (zh) SARS-CoV-2和SARS-CoV交叉中和抗体的制备及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428